ArticleFrontiers in aging neuroscience2026
Electroacupuncture alleviates cognitive impairment in mice with vascular dementia by regulating the cholinergic vasodilation system.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Electroacupuncture (EA) is a potential and reliable treatment for vascular dementia (VaD). This study aims to explore the mechanism of EA in the treatment of VaD based on neurovascular coupling. Methods: The VaD model was established by bilateral common carotid artery occlusion (BCCAO). Mice received EA at Baihui (GV20), Geshu (BL17), and Shenshu (BL23) acupoints for 7 days. Then, behavioral tests, leptomeningeal microvascular observation, immunofluorescence of basal forebrain neurons, and molecular analyses of the ACh/NO pathway were conducted. Results: EA stimulation alleviated cognitive impairment in VaD mice, dilated leptomeningeal arterioles, enhanced neuronal activity and acetylcholine expression in the basal forebrain, and increased the levels of m-1AChR, α-7-nAChR, eNOS, and NO in the frontal cortex. The m-1AChR antagonist (THP), but not the α-7-nAChR antagonist (MLA), partially reversed these regulatory effects of EA. Conclusion: EA dilates cerebral arterioles by up-regulating the ACh/NO pathway within cholinergic vasodilation system, thereby alleviating cognitive impairment induced by VaD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.